ijms-logo

Journal Browser

Journal Browser

Cutting-Edge Advances in Breast Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 895

Special Issue Editor


E-Mail Website
Guest Editor
Faculty of Medicine, Comenius University in Bratislava, Sasinkova 4, 81713108 Bratislava, Slovakia
Interests: cancer biology; cancer cell signalling; flow cytometry; cell culture; cancer immunology; inflammation; apoptosis; immunofluorescence; tumor microenvironment; neurobiology of cancer; survivorship
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

Breast cancer remains a significant global health challenge, but recent advancements in research and treatment have dramatically improved outcomes for many patients. This Special Issue will explore cutting-edge innovations that are transforming breast cancer care, including the following:  

  • Precision medicine: Tailoring treatment based on individual tumour characteristics, such as genetic mutations and molecular subtypes, is revolutionizing breast cancer care.  
  • Immunotherapy: Harnessing the power of the immune system to fight cancer, including checkpoint inhibitors and immune cell therapies, offers promising new avenues for treatment.  
  • Targeted therapies: These drugs specifically target cancer cells and their supporting pathways, minimizing harm to healthy tissues.  
  • Early detection and screening: Advances in imaging technologies and screening techniques are improving early detection and enabling earlier, more effective treatment.  
  • Personalized medicine: Integrating patient preferences, lifestyle factors, and social determinants of health into treatment plans is crucial in improving overall patient outcomes.  

For this Special Issue, we invite papers sharing new basic and translational research findings, clinical trials, and emerging technologies that are shaping the future of breast cancer care and offer hope for improved survival and quality of life for patients.

Dr. Ľuba Hunáková
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer progression and metastasis (dissemination, extravasation, angiogenesis, innervation, and metabolic reprogramming)
  • immunity and inflammation
  • targeted therapies
  • early detection and screening
  • genetics, epigenetics, mi-RNA
  • tumour microenvironment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3186 KiB  
Article
CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells
by Carla Vargas, Adam Aguirre-Ducler, Karina Cereceda, Sebastián Quijada, Nicolás Escobar-Gómez, Rodrigo L. Castillo and Matías Escobar-Aguirre
Int. J. Mol. Sci. 2025, 26(10), 4907; https://doi.org/10.3390/ijms26104907 - 20 May 2025
Cited by 1 | Viewed by 652
Abstract
Therapy resistance remains a major barrier to improving outcomes in HER2-positive breast cancer, with dormant tumor cells (DTCs) and cancer stem cells (CSCs) playing critical roles in recurrence and treatment failure. Herein, we investigated the interplay between dormancy and CSCs features in HER2-amplified [...] Read more.
Therapy resistance remains a major barrier to improving outcomes in HER2-positive breast cancer, with dormant tumor cells (DTCs) and cancer stem cells (CSCs) playing critical roles in recurrence and treatment failure. Herein, we investigated the interplay between dormancy and CSCs features in HER2-amplified breast cancer cell models and evaluated the role of the JAK1–STAT3 axis in sustaining these therapy-resistant phenotypes. Using an in vitro dormancy model induced by HER2 inhibition, we observed a reversible quiescent state characterized by decreased proliferation and viability, accompanied by a significant increase in the CSC marker CD44. CD44 expression was rapidly induced following HER2 inhibition, preceding measurable effects on cell viability, and persisted throughout the dormancy phase. CD44-positive populations showed reduced sensitivity to HER2 inhibition and displayed robust proliferative recovery upon therapy withdrawal. Functional studies revealed that the inhibition of JAK1, but not STAT3, impaired the recovery of CD44-positive populations and decreased their proliferative capacity, suggesting a critical role for JAK1 in maintaining the CSC phenotype during therapy. These findings underscore the importance of CD44 as a marker and mediator of therapy resistance and suggest that targeting CD44-positive cells or the JAK1 signaling axis could improve the efficacy of HER2-targeted therapies. Our study provides novel insights into the mechanisms underlying dormancy and CSC induction in HER2-positive breast cancer and highlights potential strategies to mitigate therapy resistance and prevent disease recurrence. Full article
(This article belongs to the Special Issue Cutting-Edge Advances in Breast Cancer)
Show Figures

Graphical abstract

Back to TopTop